National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic Evaluation of Ticagrelor (Brilique®) for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft).

Rapid Review

Commenced Completed Outcome
25/11/2010 20/01/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/07/2011 10/10/2011 Reimbursement Recommended.

We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG.

 Ticagrelor (Brilique®) summary